Connect Biopharma Holdings Ltd ADR (CNTB) Stock Price, Quote & News

Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquarte...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1040

Website: www.connectbiopharm.com

Address:

3580 CARMEL MOUNTAIN ROAD, SUITE 200, San Diego, United States

mikeywo Aug. 6 at 3:50 PM

$CNTB have a positive webinar with all great points and a transparent CEO and lose 6% the next day. You gotta love it.

0 · Reply

MorenitaScorp Aug. 4 at 1:51 PM

$CNTB 🔬

0 · Reply

Asensus2023 Aug. 3 at 7:16 AM

$CNTB “His deep expertise in drug development and commercialization will make him an invaluable asset as we continue to build a proven team of industry experts to rapidly advance the development and commercialization of rademikibart," said Kleanthis G. Xanthopoulos, Chairman of the Board of Directors, in a press release. THIS COMES OUT A PRESS RELEASE. Looking good.😁

0 · Reply

TheWings977 Jul. 29 at 8:51 PM

$CNTB brutal

0 · Reply

_www_larval_com_ Jul. 23 at 7:52 PM

$YYAI 5%[66%] $PAPL 4%[61%] $CNTB 4%[-4%] $CLLS 3%[24%] $GVH 3%[-7%] most notable movement into the final minutes of trading.

0 · Reply

Asensus2023 Jul. 23 at 5:11 PM

$CNTB this one is going back to 3 Very soon.

0 · Reply

mikeywo Jul. 23 at 2:06 PM

$CNTB drops 45c in 5 mins ? Nothing to see here. Lol

0 · Reply

mikeywo Jul. 23 at 2:04 PM

$CNTB penny flippers just got their stop Loses executed. Now they will have to chase it higher if they want back in.

0 · Reply

TheWings977 Jul. 22 at 7:32 PM

$CNTB price targets from $6.50-$7.50 so hopefully we reach that

0 · Reply

mikeywo Jul. 22 at 6:57 PM

$CNTB this has a long way to go. Up 80% year to date nothing when you have stocks going up that much in a day or week. This is the only drug in trials for acute asthma attacks and will be the first new treatment in 20 years. Eventually a chronic asthma treatment also and with an asthma market in the billions and no competition this could be a long term winner.

2 · Reply

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

Jul 21, 2025, 9:00 AM EDT - 19 days ago

Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq

Jul 18, 2025, 9:00 AM EDT - 22 days ago

Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference

Jul 17, 2025, 9:00 AM EDT - 23 days ago

Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jun 13, 2025, 9:00 AM EDT - 2 months ago

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Jun 3, 2025, 9:00 AM EDT - 2 months ago

Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

May 28, 2025, 9:00 AM EDT - 2 months ago

Connect Biopharma to Present at Two Upcoming Investor Conferences in June

May 20, 2025, 9:00 AM EDT - 2 months ago

Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

May 15, 2025, 9:00 AM EDT - 3 months ago

Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 9:00 AM EDT - 3 months ago

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD

May 13, 2025, 9:00 AM EDT - 3 months ago

Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

Apr 24, 2025, 9:00 AM EDT - 3 months ago

Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference

Apr 1, 2025, 9:00 AM EDT - 4 months ago

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

Mar 31, 2025, 4:05 PM EDT - 4 months ago

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

Mar 31, 2025, 9:00 AM EDT - 4 months ago

Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update

Mar 28, 2025, 4:05 PM EDT - 4 months ago

Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Mar 3, 2025, 8:00 AM EST - 5 months ago

Connect Biopharma to Present at Two Upcoming Investor Conferences

Oct 15, 2024, 7:30 AM EDT - 10 months ago

Attovia Therapeutics Appoints Chief Financial Officer

Oct 9, 2024, 3:55 PM EDT - 10 months ago

CNTB Stock Dips Amid Biotech Sector Volatility

Oct 2, 2024, 4:14 PM EDT - 11 months ago

CNTB Stock Surges Over 5% Amid Strong Financial Performance

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

Jun 12, 2024, 6:03 PM EDT - 1 year ago

Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jun 12, 2024, 4:15 PM EDT - 1 year ago

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

May 22, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

May 7, 2024, 6:30 AM EDT - 1 year ago

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

Apr 16, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Mar 19, 2024, 8:30 AM EDT - 1 year ago

Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

Feb 12, 2024, 4:30 PM EST - 1 year ago

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

Dec 12, 2023, 6:00 AM EST - 1 year ago

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

Dec 11, 2023, 4:05 PM EST - 1 year ago

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

Nov 21, 2023, 6:03 AM EST - 1 year ago

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

Nov 21, 2023, 6:00 AM EST - 1 year ago

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

Nov 20, 2023, 4:41 PM EST - 1 year ago

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023

Sep 12, 2023, 4:15 PM EDT - 2 years ago

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

Sep 12, 2023, 6:00 AM EDT - 2 years ago

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Aug 24, 2023, 6:21 PM EDT - 2 years ago

Connect Biopharma to Participate in Upcoming September Investor Conferences

Jul 10, 2023, 8:00 AM EDT - 2 years ago

Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology

Jul 5, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma to Participate in the SVB Securities Therapeutics Forum

Jun 1, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis

Apr 11, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update

Mar 18, 2023, 2:40 PM EDT - 2 years ago

Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms

Mar 17, 2023, 4:38 PM EDT - 2 years ago

Connect Biopharma stock up more than 40% after trial data

Mar 17, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions

Mar 6, 2023, 8:15 AM EST - 2 years ago

Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 6, 2023, 8:30 AM EST - 2 years ago

Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California

Dec 30, 2022, 7:30 AM EST - 2 years ago

Connect Biopharma Provides Business and Clinical Development Program Update

Dec 19, 2022, 8:00 AM EST - 2 years ago

Connect Biopharma to Present at the San Francisco Biotech Showcase in January

Oct 27, 2022, 4:05 PM EDT - 3 years ago

Connect Biopharma To Present at Upcoming Investor and Scientific Conferences

Oct 4, 2022, 8:56 AM EDT - 3 years ago

CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

mikeywo Aug. 6 at 3:50 PM

$CNTB have a positive webinar with all great points and a transparent CEO and lose 6% the next day. You gotta love it.

0 · Reply

MorenitaScorp Aug. 4 at 1:51 PM

$CNTB 🔬

0 · Reply

Asensus2023 Aug. 3 at 7:16 AM

0 · Reply

TheWings977 Jul. 29 at 8:51 PM

$CNTB brutal

0 · Reply

_www_larval_com_ Jul. 23 at 7:52 PM

$YYAI 5%[66%] $PAPL 4%[61%] $CNTB 4%[-4%] $CLLS 3%[24%] $GVH 3%[-7%] most notable movement into the final minutes of trading.

0 · Reply

Asensus2023 Jul. 23 at 5:11 PM

$CNTB this one is going back to 3 Very soon.

0 · Reply

mikeywo Jul. 23 at 2:06 PM

$CNTB drops 45c in 5 mins ? Nothing to see here. Lol

0 · Reply

mikeywo Jul. 23 at 2:04 PM

$CNTB penny flippers just got their stop Loses executed. Now they will have to chase it higher if they want back in.

0 · Reply

TheWings977 Jul. 22 at 7:32 PM

$CNTB price targets from $6.50-$7.50 so hopefully we reach that

0 · Reply

mikeywo Jul. 22 at 6:57 PM

2 · Reply

CarbonSpirit Jul. 22 at 5:37 PM

$CNTB Well that was a lively 5 mins, algos maybe

0 · Reply

TA_Kongen Jul. 22 at 4:26 PM

$CNTB Chinese involvement here. Founded by Zheng Wei and Wu Bin Pan

1 · Reply

TheWings977 Jul. 22 at 3:23 PM

$CNTB crazy, not much chatter going on with this one.

1 · Reply

CarbonSpirit Jul. 21 at 7:42 PM

$CNTB good news today with the announcement of the ADR being exchanged over to ordinary shares, just traded on Nasdaq, will increase liquidity, and provide a wider mix of investor instruments and investors who insist on US only market listing. Will only put improved positive momentum into the share. 😃

0 · Reply

TheWings977 Jul. 21 at 3:01 PM

$CNTB 👀

1 · Reply

KhalidsCapital Jul. 19 at 3:53 AM

GLMD is coiled, forgotten and extremely undervalued. Book value is 10x the share price. No dilution. Catalyst window ends in days. Float is thin, pressure is building, and sentiment can flip in a heartbeat. Perfect setup for a sudden reprice and history shows it can run. $TCRT $CNTB $GLSI $TCRX

0 · Reply

StockScanners Jul. 18 at 2:13 AM

$CNTB Reached 1.89, very nice, be ready for next

0 · Reply

TheWings977 Jul. 17 at 3:46 PM

$CNTB Now that they're compliant again, this thing will go right back down lmao.

1 · Reply

TheWings977 Jul. 15 at 10:43 PM

$CNTB can this be one that pops off 👀

0 · Reply

Love_To_Learn Jul. 15 at 4:11 PM

$CNTB $ONFO also need to pivot for u 2 shortly as well temp

0 · Reply

mikeywo Jul. 14 at 3:32 PM

$CNTB let the penny flippers get out from Friday and then this will start the climb again.

1 · Reply

TheWings977 Jul. 13 at 6:46 PM

$CNTB what’s the insider ownership amount and float available?

1 · Reply

Market Cap	115.01M
Revenue (ttm)	26.03M
Net Income (ttm)	-15.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-60.05%
Debt to Equity Ratio	0.00

Volume	69,900
Avg Vol	170,502
Day's Range	N/A - N/A
Shares Out	55.56M
Stochastic %K	61%
Beta	-0.09
Analysts	Strong Sell
Price Target	$6.83